Sygnature Discovery Limited
Rachel Collier currently serves as Lead Scientist at Sygnature Discovery since November 2023. Prior to this role, Rachel held positions as Senior Scientist at BenevolentAI from October 2021 to August 2023, and as Scientist at Charles River Laboratories from June 2017 to October 2021. Earlier experience includes a Research Scientist role at AstraZeneca from November 2015 to May 2017, and self-employment in dog training from September 2011 to November 2014. Rachel's career began at GSK, where time was spent as a Research Scientist from July 1991 to October 2011. Rachel earned a Bachelor of Science degree in Applied Biology from the University of Hertfordshire between 1994 and 1999.
This person is not in any teams
This person is not in any offices
Sygnature Discovery Limited
2 followers
Sygnature Discovery are a leading drug discovery CRO with expertise across a range of therapeutic and biological target classes. An expert partner in disciplines including Medicinal and Computational Chemistry, In Vitro and In Vivo Pharmacology, DMPK, supported by informatics.